Curis (FRA:CUS1) Cyclically Adjusted Revenue per Share: €0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CUS1 Curis Inc FRA:CUS1
55 GF Score
Price €3.93
GF Value €1.29
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Curis Cyclically Adjusted Revenue per Share?

Curis FRA:CUS1 -6.32% 55 Cyclically Adjusted Revenue per Share is €0.00 as of Mar. 2026. GuruFocus rates FRA:CUS1 with a GF Score™ of 55/100 and a GF Value™ of €1.29 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Curis's adjusted revenue per share for the three months ended in Mar. 2026 was €0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Curis's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -17.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -17.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -13.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Curis was -3.40% per year. The lowest was -19.20% per year. And the median was -10.00% per year.

As of today (2026-07-17), Curis's current stock price is €3.93. Curis's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €0.00. Curis's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Curis was 1.22. The lowest was 0.01. And the median was 0.11.


Curis  (FRA:CUS1) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Curis was 1.22. The lowest was 0.01. And the median was 0.11.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Curis Cyclically Adjusted Revenue per Share Related Terms


Curis Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Curis's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curis Cyclically Adjusted Revenue per Share Chart

Curis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,595.54 3,177.48 1,497.24 2,150.25 1,697.42

Curis Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,202.01 1,633.95 1,658.83 1,697.42 0.00

FRA:CUS1 vs CALC, ICU, TRAW: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Curis's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curis Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curis's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Curis's Cyclically Adjusted PS Ratio falls into.


FRA:CUS1
55GF Score
Curis Inc FRA:CUS1
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curis Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Curis's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/330.2130*330.2130
=0.000

Current CPI (Mar. 2026) = 330.2130.

Curis Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 23.000 241.018 31.512
201609 23.742 241.428 32.473
201612 31.986 241.432 43.748
201703 28.056 243.801 38.000
201706 25.472 244.955 34.338
201709 28.096 246.819 37.589
201712 33.610 246.524 45.020
201803 24.120 249.554 31.916
201806 24.313 251.989 31.860
201809 29.398 252.439 38.455
201812 29.181 251.233 38.355
201903 18.843 254.202 24.477
201906 22.325 256.143 28.781
201909 31.241 256.759 40.178
201912 35.639 256.974 45.796
202003 28.512 258.115 36.476
202006 21.172 257.797 27.119
202009 17.118 260.280 21.717
202012 15.067 260.474 19.101
202103 8.031 264.877 10.012
202106 8.284 271.696 10.068
202109 11.279 274.310 13.578
202112 12.114 278.802 14.348
202203 8.157 287.504 9.369
202206 9.886 296.311 11.017
202209 12.192 296.808 13.564
202212 11.307 296.797 12.580
202303 8.864 301.836 9.697
202306 8.380 305.109 9.069
202309 9.283 307.789 9.959
202312 8.554 306.746 9.208
202403 6.640 312.332 7.020
202406 8.127 314.175 8.542
202409 8.892 315.301 9.313
202412 8.318 315.605 8.703
202503 5.179 319.799 5.348
202506 3.777 322.561 3.867
202509 3.452 324.800 3.510
202512 1.232 324.054 1.255
202603 0.000 330.213 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.00 mean?
Curis (FRA:CUS1) has a Cyclically Adjusted Revenue per Share of €0.00 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Curis and its competitors.
Is Curis' Cyclically Adjusted Revenue per Share too high?
Curis' current Cyclically Adjusted Revenue per Share is €0.00. Overall, Curis has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Curis' Cyclically Adjusted Revenue per Share compare to CALC and ICU?
Curis' Cyclically Adjusted Revenue per Share of €0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Curis and its competitors. Curis's current Cyclically Adjusted Revenue per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis stock overvalued right now?
Based on GuruFocus' analysis, Curis (FRA:CUS1) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.29, compared to a current price of €3.93 — trading 204.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.00. Curis' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Curis (FRA:CUS1), the current Cyclically Adjusted Revenue per Share is €0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Curis (FRA:CUS1) Overvalued in 2026?

Based on GuruFocus' analysis, Curis stock appears to be overvalued. The current stock price of €3.93 is trading 204.7% above its estimated GF Value™ of €1.29. GuruFocus considers Curis to be Significantly Overvalued.

Key valuation signals for FRA:CUS1:

  • Cyclically Adjusted Revenue per Share: €0.00
  • GF Value™: €1.29 vs. price of €3.93 (204.7% above fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the FRA:CUS1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Curis Business Description

Other Exchanges CRIS:USA
Address 128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
55GF Score

Get the complete analysis for FRA:CUS1

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.93
Price
€1.29
GF Value